Same Drug Class

Imatinib vs Nivolumab

Imatinib vs Nivolumab: Overview

This comparison examines the pharmacological differences between Imatinib and Nivolumab.

Mechanism of Action

Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Imatinib — 18 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Imatinib — C29H31N7O.

Molecular Weight: Imatinib — 493.6030 g/mol.

Type: Imatinib — Small molecule; Nivolumab — Antibody.